QuidelOrtho’s infectious disease test portfolio spans the healthcare continuum from point-of-care settings to high-throughput laboratories and is critical in addressing the growing syphilis epidemic ...

Ortho Clinical Diagnostics announced that it has received CE mark for Ortho's VITROS® XT 7600 Integrated System. By combining Ortho's proprietary dry slide technology with sophisticated digital ...

QuidelOrtho Corporation QDEL recently announced the FDA 510(k) clearance for its VITROS syphilis assay as part of its menu, which is likely to strengthen its position as a leader in infectious disease ...

Novel diagnostic technology enables powerful data intelligence, operational improvements and other enhancements in the lab RARITAN, New Jersey, July 24, 2018 /PRNewswire/ -- Ortho Clinical Diagnostics ...

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions, designed to cover most typical lab tests with a smaller footprint ...

RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...

QuidelOrtho Receives FDA 510(k) Clearance for its VITROS Syphilis Assay SAN DIEGO, August 29, 2024--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") has received U.S. Food and ...